Clinical Research Directory
Browse clinical research sites, groups, and studies.
Topiramate and Schizophrenia: Effects on Weight and Psychopathology
Sponsor: Centre for Addiction and Mental Health
Summary
Clozapine is the sole AP agent with superiority in treatment refractory schizophrenia, but it also is associated with the greatest risk of weight gain and other metabolic abnormalities. Topiramate, an anticonvulsant agent, possesses a weight-reducing effect. Furthermore, some studies have suggested that Topiramate may be associated with improvements in psychopathology in treatment refractory schizophrenia. Here the investigators propose to determine the role of topiramate for augmentation purposes (psychopathology) and as an adjunctive pharmacological intervention for weight loss in overweight/obese individuals with Ultra-Treatment Resistant Schizophrenia or Schizoaffective disorder taking clozapine.
Official title: Topiramate in Treatment Refractory Psychotic Illness: Effects on Weight Gain and Psychopathology
Key Details
Gender
All
Age Range
17 Years - 59 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2016-05
Completion Date
2026-08
Last Updated
2026-05-28
Healthy Volunteers
No
Conditions
Interventions
Topiramate
Topiramate capsules starting with 25 mg b.i.d with an incremental increase of 25 mg b.i.d weekly upto a maximum of 100 mg b.i.d.
Placebo
Placebo capsules visually identical to those containing topiramate will be administered.
Locations (1)
Center for Addiction and Mental Health
Toronto, Ontario, Canada